Inking Ono deal, Cyclenium searches space between small and large molecules for new candidates

14 December 2017

Privately-held Canadian firm Cyclenium Pharma has signed a drug discovery agreement with Ono Pharmaceutical (TYO: 4528), the Japanese firm whose fortune was made by the discovery of the groundbreaking I-O therapy Opdivo (nivolumab).

Cyclenium brings to the table its proprietary CMRT ‘macrocyclic’ technology, which targets the molecular space between traditional small molecules and large biologics.

The company was spun out from Tranzyme Pharma in 2013, one of the pioneers of the particular macrocycle technology the company is exploiting.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK